LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announces SIVEXTRO™ (tedizolid phosphate) indicated for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) is now available in the U.S. in once-daily I.V. and oral formulations. Approved by the U.S. Food and Drug Administration (FDA) on June 20, 2014, SIVEXTRO addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)— which has been categorized by the U.S. Centers for Disease Control and Prevention (CDC) as a serious public health threat.
“We are pleased to formally announce the availability of the I.V. version of SIVEXTRO for physician and hospital order in the U.S.,” said Rob Perez, President and Chief Operating Officer of Cubist. “SIVEXTRO oral has been on the market since late June. We believe the features and utility of SIVEXTRO offers physicians an effective option to treat acute bacterial skin and skin structure infections in a number of real-life patient settings—from the hospital to the home.”
Help employers find you! Check out all the jobs and post your resume.
